Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients

Leukemia Research

Volumn 29, Issue 10, 2005, Pages 1109-1116

  Perea, G ^a   Domingo, A ^a   Villamor, N ^a   Palacios, C ^a   Junca J ^a   Torres, P ^a   Llorente, A ^a   Fernandez C ^a   Tormo, M ^a   Queipo De Llano, M P ^a   Bargay, J ^a   Gallart, M ^a   Florensa, L ^a   Vivancos, P ^a   Marti J M ^a   Font, Ll ^a   Berlanga, J ^a   Esteve, J ^a   Bueno, J ^a   Ribera, J M ^a   Brunet, S ^a   Sierra, J ^a   Nomdedeu J F ^a   more..

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

AML; CD2; CD36; CD7; Prognostic factors

Indexed keywords

CD2 ANTIGEN; CD36 ANTIGEN; FLUOROCHROME; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER SURVIVAL; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STAINING; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; ANTIGENS, CD36; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INVERSION, CHROMOSOME; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 23844487734     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.02.015     Document Type: Article

References (40)

1. M.C. Bene, G. Castoldi, W. Knapp, W.D. Ludwig, E. Matutes, and A. Orfao European Group for the Immunological Characterization of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias Leukemia 9 1995 1783 1786
2. M.C. Béné, M. Bernier, G. Castoldi, G.C. Faure, W. Knapp, and W.D. Ludwig Impact of immunophenotyping on management of acute leukemias Haematologica 84 1999 1024 1034
3. R.O. Casasnovas, F.K. Slimane, R. Garand, G.C. Faure, L. Campos, and V. Deneys Immunological classification of acute myeloblastic leukemias: relevance to patient outcome Leukemia 17 2003 515 527
4. + lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia Cytometry 38 1999 70 75
5. J.F. San Miguel, A. Martínez, A. Macedo, M.B. Vidriales, C. López-Berges, and M. González Immunophenotyping investigation of minimal residual disease is a useful aproach for predicting relapse in acute myeloid leukemia patients Blood 90 1997 2465 2470
6. D. Raspadori, D. Damiani, M. Lenoci, D. Roncelli, N. Testoni, and G. Nardi CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis Leukemia 15 2001 1161 1164
7. R.B. Geller, M. Zahurak, C.A. Hurwitz, P.J. Burke, J.E. Karp, and S. Piantadosi Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10) Br J Hematol 76 1990 340 347
8. R. Repp, U. Schaekel, G. Helm, C. Thiede, S. Soucek, and U. Pascheberg Immunophenotyping is an independent factor for risk stratification in AML Cytometry 53B 2003 11 19
9. G. Valet, R. Repp, H. Link, A. Ehninger, M Gramatzki The SHG-AML study group Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters Cytometry 53B 2003 4 10
10. H. Chang, F. Salma, Q. Yi, B. Patterson, B. Brien, and M.D. Minden Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia Leuk Res 28 2004 43 48
11. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, and G. Harrison The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial Blood 92 1998 2322 2333
12. M.L. Slovak, K.J. Kopecky, P.A. Cassileth, D.H. Harrington, K.S. Theil, and A. Mohamed Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
13. A.K. Burnett, K. Wheatley, A.H. Goldstone, R.F. Stevens, I.M. Hann, and J.H. Rees The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial Br J Hematol 118 2002 385 400
14. R.E. Gale FLT3 mutations and leukaemia Br J Hematol 122 2003 523 538
15. Mitelman F, editor. ISCN. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995.
16. L. Muñoz, J.F. Nomdedéu, N. Villamor, R. Guardia, D. Colomer, and J.M. Ribera Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells Leukemia 17 2003 76 82
17. J. Gabert, E. Beillard, V.H. van der Velden, W. Bi, D. Grimwade, and N. Pallisgaard Standarization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe against cancer program Leukemia 17 2003 2318 2357
18. M. Nakao, S. Yokota, T. Iwai, H. Kanebo, S. Horiike, and K. Kashima Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 19 1996 1911 1918
19. L. Muñoz, A. Aventín, N. Villamor, J. Juncà, G. Acebedo, and A. Domingo Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication Haematologica 88 2003 637 645
20. B.D. Cheson, P.A. Cassilech, D.R. Head, C.A. Schiffer, J.M. Bennett, and C.D. Bloomfield Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 8 1990 813 819
21. L. Muñoz, J.F. Nomdedéu, O. López, M.J. Carnicer, M. Bellido, and A. Aventín Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies Haematologica 86 2001 1261 1269
22. H.J. Adriaansen, P.W. Soeting, I.L. Wolvers-Tettero, and J.J. van Dongen Immunoglobulin and T-cell receptor gene rearrangements in acute non-lymphocytic leukemias. Analysis of 54 cases and a review of the literature Leukemia 5 1991 744 751
23. I. Sánchez, J.F. San Miguel, J. Corral, C. Martín, R. Pérez, and M. González Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells Br J Hematol 89 1995 104 109
24. A.L. Armesilla, D. Calvo, and M.A. Vega Structural and functional characterization of the human CD36 gene promoter J Biol Chem 271 1996 7781 7787
25. D.E. Greenwalt, R.H. Lipsky, C.F. Ockenhouse, H. Ikeda, N.N. Tandon, and G.A. Jamieson Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine Blood 80 1992 1105 1115
26. A.L. Armesilla, and M.A. Vega Structural organization of the gene for human CD36 glycoprotein J Biol Chem 269 1994 18985 18991
27. Y. Moodley, P. Rigby, C. Bundell, S. Bunt, H. Hayashi, and N. Misso Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36 Am J Pathol 162 2003 771 779
28. S.R. Wolman, H. Gundacker, F.R. Appelbaum, and M.L. Slovak Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Soutwest Oncology Group study Blood 100 2002 29 35
29. K. Virtaneva, F.A. Wright, S.M. Tanner, B. Yuan, W.J. Lemon, and M.A. Caligiuri Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics Proc Natl Acad Sci USA 98 2001 1124 1129
30. E. Paietta, P. Wiernik, J. Andersen, J. Bennet, and J. Yunis Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression Blood 82 1993 2595
31. + immature cells Br J Hematol 97 1997 656 658
32. B. Lenormand, J.P. Vannier, M.C. Bene, A. Falkenrodt, C. Bayle, and M. Favre CD2+ CD19+ acute lymphoblastic leukaemia in 16 children and adults: clinical and biological features Br J Hematol 83 1993 580 588
33. F.M. Uckun, P.G. Steinherz, H. Sather, M. Trigg, D. Arthur, and D. Tubergen CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group Study Blood 88 1996 4288 4295
34. J. Delaunay, N. Vey, T. Leblanc, P. Fenaux, F. Rigal-Huguet, and F. Witz Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup Blood 102 2003 462 469
35. B. Lutterbach, Y. Hou, K.L. Durst, and S.W. Hiebert The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor Proc Natl Acad Sci USA 96 1999 12822 12827
36. H.J. Adriaansen, P.A.W. te Boekhorst, A.M. Hagemeijer, C.E. van der Schoot, H.R. Delwel, and J.J.M. van Dongen Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression Blood 81 1993 3043 3051
37. A. Biondi, A. Luciano, R. Bassan, D. Mininni, G. Specchia, and E. Lanzi CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint Leukemia 9 1995 1461 1466
38. D.F. Claxton, C.L. Reading, L. Nagarajan, Y. Tsujimoto, B.S. Andersson, and E. Estey Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia Blood 80 1992 582 586
39. R. Suzuki, K. Yamamoto, M. Seto, Y. Kagami, M. Ogura, and Y. Yatabe CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity Blood 90 1997 2417 2428
40. + acute myeloblastic leukemia/acute lymphoblastic leukemia Blood 82 1993 3445 3451